Pharmaceutical stabilization of mast cells attenuates experimental atherogenesis in low-density lipoprotein receptor-deficient mice

Atherosclerosis

Volumn 229, Issue 2, 2013, Pages 304-309

  Wang, Jing ^a   Sjöberg, Sara ^a   Tia, Viviane ^a   Secco, Blandine ^a   Chen, Han ^a   Yang, Min ^a   Sukhova, Galina K ^a   Shi, Guo Ping ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; C48 80; Cromolyn; LDL receptor deficient mice; Mast cell

Indexed keywords

CHOLESTEROL; CROMOGLYCATE DISODIUM; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ARCH; ARTICLE; ATHEROGENESIS; ATHEROGENIC DIET; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; LIPID STORAGE; MALE; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; THORACIC AORTA;

ATHEROSCLEROSIS; C48/80; CROMOLYN; LDL RECEPTOR-DEFICIENT MICE; MAST CELL;

ANIMALS; ANTI-ASTHMATIC AGENTS; ATHEROSCLEROSIS; CROMOLYN SODIUM; DISEASE MODELS, ANIMAL; LIPOPROTEINS, LDL; MALE; MAST CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; P-METHOXY-N-METHYLPHENETHYLAMINE; RECEPTORS, LDL; TRIGLYCERIDES; VASCULITIS;

EID: 84880425554     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.05.025     Document Type: Article

References (42)

1. Constantinides P. Mast cells and susceptibility to experimental atherosclerosis. Science 1953, 117:505-506.
2. Cairns A., Constantinides P. Mast cells in human atherosclerosis. Science 1954, 120:31-32.
3. Lindstedt K.A., Kovanen P.T. Mast cells in vulnerable coronary plaques: potential mechanisms linking mast cell activation to plaque erosion and rupture. Curr Opin Lipidol 2004, 15:567-573.
4. Kovanen P.T. Mast cells in atherogenesis: actions and reactions. Curr Atheroscler Rep 2009, 11:214-219.
5. Xu J.M., Shi G.P. Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases. Endocr Rev 2012, 33:71-108.
6. He A., Shi G.P. Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases. Curr Pharm Des 2013, 19:1114-1125.
7. Zhang J., Alcaide P., Liu L., et al. Regulation of endothelial cell adhesion molecule expression by mast cells, macrophages, and neutrophils. PLoS One 2011, 6:e14525.
8. Sun J., Sukhova G.K., Wolters P.J., et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 2007, 13:719-724.
9. Cheng X.W., Shi G.P., Kuzuya M., Sasaki T., Okumura K., Murohara T. Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation 2012, 125:1551-1562.
10. Sjöberg S., Shi G.P. Cysteine protease cathepsins in atherosclerosis and abdominal aortic aneurysm. Clin Rev Bone Miner Metab 2011, 9:138-147.
11. Sun J., Zhang J., Lindholt J.S., et al. Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation 2009, 120:973-982.
12. Zhang J., Sun J., Lindholt J.S., et al. Mast cell tryptase deficiency attenuates mouse abdominal aortic aneurysm formation. Circ Res 2011, 108:1316-1327.
13. den Dekker W.K., Tempel D., Bot I., et al. Mast cells induce vascular smooth muscle cell apoptosis via a toll-like receptor 4 activation pathway. Arterioscler Thromb Vasc Biol 2012, 32:1960-1969.
14. Mäyränpää M.I., Heikkilä H.M., Lindstedt K.A., Walls A.F., Kovanen P.T. Desquamation of human coronary artery endothelium by human mast cell proteases: implications for plaque erosion. Coron Artery Dis 2006, 17:611-621.
15. Judström I., Jukkola H., Metso J., Jauhiainen M., Kovanen P.T., Lee-Rueckert M. Mast cell-dependent proteolytic modification of HDL particles during anaphylactic shock in the mouse reduces their ability to induce cholesterol efflux from macrophage foam cells exvivo. Atherosclerosis 2010, 208:148-154.
16. Lee M., Calabresi L., Chiesa G., Franceschini G., Kovanen P.T. Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2002, 22:1475-1481.
17. Yeong P., Ning Y., Xu Y., Li X., Yin L. Tryptase promotes human monocyte-derived macrophage foam cell formation by suppressing LXRalpha activation. Biochim Biophys Acta 2010, 1801:567-576.
18. Lee M., Kovanen P.T., Tedeschi G., Oungre E., Franceschini G., Calabresi L. Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux. JLipid Res 2003, 44:539-546.
19. Favari E., Lee M., Calabresi L., et al. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. JBiol Chem 2004, 279:9930-9936.
20. Barish G.D., Evans R.M. PPARs and LXRs: atherosclerosis goes nuclear. Trends Endocrinol Metab 2004, 15:158-165.
21. Joseph S.B., McKilligin E., Pei L., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 2002, 99:7604-7609.
22. Bot I., Bot M., van Heiningen S.H., et al. Mast cell chymase inhibition reduces atherosclerotic plaque progression and improves plaque stability in ApoE-/- mice. Cardiovasc Res 2011, 89:244-252.
23. Smith D.D., Tan X., Raveendran V.V., Tawfik O., Stechschulte D.J., Dileepan K.N. Mast cell deficiency attenuates progression of atherosclerosis and hepatic steatosis in apolipoprotein E-null mice. Am J Physiol Heart Circ Physiol 2012, 302:H2612-H2621.
24. Heikkilä H.M., Trosien J., Metso J., et al. Mast cells promote atherosclerosis by inducing both an atherogenic lipid profile and vascular inflammation. JCell Biochem 2010, 109:615-623.
25. Bot I., de Jager S.C., Zernecke A., et al. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation 2007, 115:2516-2525.
26. Bot I., de Jager S.C., Bot M., et al. The neuropeptide substance P mediates adventitial mast cell activation and induces intraplaque hemorrhage in advanced atherosclerosis. Circ Res 2010, 106:89-92.
27. de Vries M.R., Wezel A., Schepers A., et al. Complement factor C5a as mast cell activator mediates vascular remodelling in vein graft disease. Cardiovasc Res 2013, 97:311-320.
28. Mach F., Schönbeck U., Sukhova G.K., Atkinson E., Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998, 394:200-203.
29. Sukhova G.K., Zhang Y., Pan J.H., et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. JClin Invest 2003, 111:897-906.
30. Thakurdas S.M., Melicoff E., Sansores-Garcia L., et al. The mast cell-restricted tryptase mMCP-6 has a critical immunoprotective role in bacterial infections. JBiol Chem 2007, 282:20809-20815.
31. Stelekati E., Bahri R., D'Orlando O., et al. Mast cell-mediated antigen presentation regulates CD8+ T cell effector functions. Immunity 2009, 31:665-676.
32. Compton S.J., Cairns J.A., Holgate S.T., Walls A.F. The role of mast cell tryptase in regulating endothelial cell proliferation, cytokine release, and adhesion molecule expression: tryptase induces expression of mRNA for IL-1 beta and IL-8 and stimulates the selective release of IL-8 from human umbilical vein endothelial cells. JImmunol 1998, 161:1939-1946.
33. Streumer J. Treatment of asthma with DSCG in juveniles during and after hospitalization. Respiration 1970, 27(Suppl.):363-368.
34. Liu J., Divoux A., Sun J., et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med 2009, 15:940-945.
35. Choy K., Beck K., Png F.Y., et al. Processes involved in the site-specific effect of probucol on atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler Thromb Vasc Biol 2005, 25:1684-1690.
36. Lewis P., Stefanovic N., Pete J., et al. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation 2007, 115:2178-2187.
37. Niwa T., Wada H., Ohashi H., et al. Interferon-gamma produced by bone marrow-derived cells attenuates atherosclerotic lesion formation in LDLR-deficient mice. JAtheroscler Thromb 2004, 11:79-87.
38. Kitamoto S., Sukhova G.K., Sun J., et al. Cathepsin L deficiency reduces diet-induced atherosclerosis in low-density lipoprotein receptor-knockout mice. Circulation 2007, 115:2065-2075.
39. Gotsman I., Grabie N., Gupta R., et al. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 2006, 114:2047-2055.
40. Gotsman I., Grabie N., Dacosta R., Sukhova G., Sharpe A., Lichtman A.H. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. JClin Invest 2007, 117:2974-2982.
41. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21:1876-1890.
42. Nishimura S., Manabe I., Nagasaki M., et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009, 15:914-920.